Entrada Therapeutics, Inc.
TRDA
$6.09
-$0.70-10.31%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -170.23% | 5.52% | 1,081.69% | 352.42% | 226.80% |
| Total Depreciation and Amortization | 14.50% | 17.04% | 32.81% | 33.68% | 47.60% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 56.87% | 52.84% | 7.71% | -8.73% | -20.81% |
| Change in Net Operating Assets | 48.96% | 23.93% | -187.19% | -162.79% | -170.31% |
| Cash from Operations | -772.86% | 38.79% | -129.73% | -111.99% | -112.50% |
| Capital Expenditure | 37.49% | 27.59% | 43.75% | 34.55% | 8.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -45.22% | 31.81% | 81.44% | 56.02% | 115.23% |
| Cash from Investing | -47.17% | 31.53% | 79.91% | 55.20% | 111.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.96% | 5,940.95% | 389.49% | 393.90% | 403.17% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -97.98% | 5,940.30% | 389.44% | 393.85% | 403.17% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -206.88% | 99.62% | 49.74% | 1,931.14% | 1,048.49% |